Advertisement

Drug Investigation

, Volume 8, Issue 2, pp 95–103 | Cite as

Effect of BN 50730, a Specific PAF Antagonist, on PAF-Induced Platelet Aggregation and Skin Responses in Healthy Human Volunteers

  • Jacques Duchier
  • Caroline Auriche
  • Philippe Guinot
Original Research Article

Summary

The effect of the oral administration of BN 50730, a specific synthetic plate-let-activating factor (PAF) receptor antagonist, on 2 recognised PAF-induced reactions (ex vivo platelet aggregation and immediate cutaneous responses), was assessed through 3 double-blind placebo-controlled studies in healthy, non-allergic male volunteers. Platelet aggregation showed a peak level of inhibition 4 hours following the single administration of either a 10, 20 or 40mg dose. A dose-response relationship was observed regarding the duration of the effect; while lasting less than 12 hours for the 10mg dose, inhibition was still evident 16 hours after administration of the 40mg dose. Wheal and flare reactions to intradermal PAF (400ng) were significantly inhibited following single dose administration of either 10, 20 or 40mg of BN 50730. The 40mg dose inhibited the flare reaction by more than 90% at 8 hours post-treatment. Treatment with either 20 or 40mg of BN 50730 twice daily for 7 days resulted in a reduction in the cutaneous responses to PAF after the last dose by at least 80% compared with placebo in both treatment groups, the 2 doses being almost equally effective. The results indicate that BN 50730 is a potent PAF antagonist and provide interesting information for testing the product at 40 or 80mg dose levels in twice-daily phase II clinical studies.

Keywords

Platelet Aggregation Platelet Activate Factor Drug Invest Induce Platelet Aggregation Cutaneous Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Braquet P, Touqui L, Shen TY, et al. Perspectives in platelet-activating factor research. Pharmacol Rev 1987 39: 97–145PubMedGoogle Scholar
  2. 2.
    Barnes PJ, Chung KF, Page CP. Platelet-activating factor as a mediator of allergic disease. J Allergy Clin Immunol 1988; 81: 919–34PubMedCrossRefGoogle Scholar
  3. 3.
    Koltai M, Hosford D, Guinot Ph, et al. Platelet activating factor (PAF): A review of its effects, antagonists and possible future clinical implications (Part I). Drugs 1991; 42: 9–29PubMedCrossRefGoogle Scholar
  4. 4.
    Koltai M, Hosford D, Guinot Ph, et al. Platelet activating factor (PAF): A review of its effects, antagonists and possible future clinical implications (Part II). Drugs 1991; 42: 92–4Google Scholar
  5. 5.
    Braquet P, Chabrier PE, Mencia-Huerta JM. The promise of PAF-acether antagonists. In: Lewis et al. editors. Advances in Inflammation Research. Vol. 12, New York, Raven Press, 1988; 135–57Google Scholar
  6. 6.
    Braquet P, Godfroid JJ. PAF-acether specific binding sites. 2. Design of specific antagonists. Trends Pharmacol Sci 1986; XX: 397–403CrossRefGoogle Scholar
  7. 7.
    Saunders RN, Handley DA. Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol 1987; 27: 237–55PubMedCrossRefGoogle Scholar
  8. 8.
    Chung KF, Barnes PJ. PAF antagonists. Their potential therapeutic role in asthma. Drugs 1988; 35: 93–103PubMedCrossRefGoogle Scholar
  9. 9.
    Hosford D, Page CP, Barnes PJ, et al. PAF-receptor antagonists. In Barnes et al. editors. Platelet activating factor and human disease. Oxford, Blackwell, 1989; 82–116Google Scholar
  10. 10.
    Roubin R, Arnoux B, Benveniste J. Rôle du PAF-acether et perspectives thérapeutiques. Revue Médicale 1982; 23: 1217–21Google Scholar
  11. 11.
    Lagente V, Boichot E, Carré C, et al. Effects of the platelet activating factor antagonists BN 52021 and BN 50730 on antigen-induced bronchial hyperresponsiveness and eosinophil infiltration in lung from sensitized guinea-pig. Clin Exp Allergy, in pressGoogle Scholar
  12. 12.
    Martins MA, Pires ALA, Silva PMR, et al. Effect of the hetrazepine BN 50730 on the pleural exudatory and cellular response triggered by PAF in rats. J Lipid Mediat, in pressGoogle Scholar
  13. 13.
    Lagente V, Boichot E, Chadi S, et al. Effect of the platelet activating factor (PAF) antagonist, BN 50730, on the increased production of Superoxide anions by alveolar macrophages from antigen-exposed sensitized guinea-pigs. Fundam Clin Pharmacol 1991; 5(5): 426Google Scholar
  14. 14.
    Adamus WS, Heuer H, Meade CJ. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers. Methods Find Exp Clin Pharmacol 1989; 11: 415–20PubMedGoogle Scholar
  15. 15.
    Buisine E, Chrétien J. Structure-activity relationships in PAF antagonist series: Comparison of ginkgolides with other chemical frameworks. In: Braquet, editor. Ginkolides -Chemistry, Biology, Pharmacology and Clinical Perspectives, Vol. 2, Barcelona, JR. Prous Science Publishers, 1989; 37–48Google Scholar
  16. 16.
    Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet-activating factor in man. Lancet 1987; 1: 248–51PubMedCrossRefGoogle Scholar
  17. 17.
    Guinot P, Braquet P, Duchier J, et al. Inhibition of PAF-acetherinduced wheal and flare reaction in man by a specific PAF antagonist. Prostaglandins 1986; 32: 160–3PubMedCrossRefGoogle Scholar
  18. 18.
    Hayes JP, Ridge SM, Griffith S, et al. Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man. J Allergy Clin Immunol 1991; 88: 83–8PubMedCrossRefGoogle Scholar
  19. 19.
    Lalau-Keraly C, Benveniste J. Desensitization of rabbit platelets by platelet activating factor and derivatives. British Specific Journal of Haematology 1982; 51: 313–32Google Scholar
  20. 20.
    Deshazo RD, Levinson AI, Dvorak HF, et al. The late phase skin reaction: evidence for activation of the coagulation system in an IgE-dependant reaction in man. J Immunol 1979; 122: 692–8PubMedGoogle Scholar
  21. 21.
    Burke LA, Lee TH. Effect of BN 52063 on clinical and histological effects of PAF in atopic skin. In Braquet, editor. Ginkgolides - Chemistry, Biology, Pharmacology and Clinical Perspectives, Vol. 2, Barcelona, JR. Prous Science Publishers, 1989; 879–85Google Scholar
  22. 22.
    Markey AC, Barker JNWN, Archer CB, et al. Platelet activating factor-induced clinical and histopathological responses in atopic skin and their modification by the platelet activating factor antagonist BN 52063. J Am Acad Dermatol 1990; 23: 263–8PubMedCrossRefGoogle Scholar
  23. 23.
    Roberts NM, Page CP, Chung KF, et al. Effect of a PAF antagonist, BN 52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects. J Allergy Clin Immunol 1988; 82: 236–41PubMedCrossRefGoogle Scholar
  24. 24.
    Kuitert LM, Hui KP, Uthayarkumar S, et al. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am Rev Respir Dis 1993; 147: 82–6PubMedCrossRefGoogle Scholar
  25. 25.
    Braquet P. The ginkgolides: potent platelet-activating factor antagonists isolated from Ginkgo biloba L: chemistry, pharmacology, and clinical applications. Drugs Future 1987; 12: 643–99Google Scholar
  26. 26.
    Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Jacques Duchier
    • 1
  • Caroline Auriche
    • 2
  • Philippe Guinot
    • 2
  1. 1.Hôpital de St CloudSaint-CloudParisFrance
  2. 2.Institut Henri BeaufourGroupe Beaufour-IpsenParisFrance

Personalised recommendations